Lunai Bioworks (NASDAQ:LNAI) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Lunai Bioworks (NASDAQ:LNAI) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Lunai Bioworks Price Performance

NASDAQ:LNAI opened at $0.55 on Friday. Lunai Bioworks has a 52 week low of $0.52 and a 52 week high of $14.00. The company’s 50-day simple moving average is $0.87. The firm has a market cap of $13.19 million, a PE ratio of -7.79 and a beta of 0.46.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.